Poisoning and Toxic Effects of Drugs without MCC DRG Reimbursement

DRG 918 addresses hospital admissions for poisoning and toxic effects of drugs without Major Complication or Comorbidity. It defines the clinical scope for reimbursement and determines grouping for Medicare inpatient payment under the prospective payment system.

DRG 918 Overview

DRG 918 covers inpatient admissions for poisoning and toxic effects of drugs when no Major Complication or Comorbidity is present. It includes patients treated for drug overdoses or adverse toxic reactions that do not meet higher severity thresholds. This DRG matters for Medicare payment because it groups similar resource-use cases for standardized reimbursement under the inpatient prospective payment system. Proper assignment affects hospital payment and case mix reporting.

Acute emergency intervention trials: randomized or observational studies testing different immediate management strategies for patients hospitalized with drug poisoning or toxic effects, such as timing and use of decontamination methods, antidote administration protocols, or airway and hemodynamic support bundles. These studies typically enroll adult and pediatric inpatients presenting to emergency departments with confirmed or suspected overdose/toxicity and compare short-term outcomes like time to stabilization, need for ICU care, and in-hospital mortality. Results inform clinicians about best practices in the acute stabilization phase and help payers understand resource utilization drivers (e.g., ICU admission, antidote costs) for this DRG.
Comparative effectiveness and safety studies of antidote and supportive care strategies: prospective cohort studies or pragmatic trials comparing different antidotes, dosing regimens, duration of monitoring, or adjunctive therapies in subgroups defined by agent class (e.g., opioids, benzodiazepines, acetaminophen) and comorbidity burden. These investigations focus on clinically relevant endpoints such as organ failure rates, length of stay, readmission for recurrent toxicity, and adverse events related to interventions, enrolling patients across wards and critical care units. Findings guide evidence-based protocol development, enable hospitals to standardize care pathways, and assist payers in evaluating cost-effectiveness of specific treatments and monitoring strategies for reimbursement and coverage policies.
Post-discharge outcomes and prevention research: longitudinal observational studies and interventional trials targeting transition-of-care and secondary prevention in survivors of poisoning, including programs for substance use disorder referral, mental health follow-up, medication safety education, and monitoring for delayed toxic effects. These studies enroll patients discharged after an acute toxic exposure and measure outcomes such as 30- and 90-day readmission, repeat overdose, engagement in outpatient treatment, and long-term functional status. Results are important to providers aiming to reduce recurrent events and to payers interested in downstream cost savings from reduced readmissions and improved outpatient care coordination for this high-risk population.

Acute emergency intervention trials: randomized or observational studies testing different immediate management strategies for patients hospitalized with drug poisoning or toxic effects, such as timing and use of decontamination methods, antidote administration protocols, or airway and hemodynamic support bundles. These studies typically enroll adult and pediatric inpatients presenting to emergency departments with confirmed or suspected overdose/toxicity and compare short-term outcomes like time to stabilization, need for ICU care, and in-hospital mortality. Results inform clinicians about best practices in the acute stabilization phase and help payers understand resource utilization drivers (e.g., ICU admission, antidote costs) for this DRG.
Comparative effectiveness and safety studies of antidote and supportive care strategies: prospective cohort studies or pragmatic trials comparing different antidotes, dosing regimens, duration of monitoring, or adjunctive therapies in subgroups defined by agent class (e.g., opioids, benzodiazepines, acetaminophen) and comorbidity burden. These investigations focus on clinically relevant endpoints such as organ failure rates, length of stay, readmission for recurrent toxicity, and adverse events related to interventions, enrolling patients across wards and critical care units. Findings guide evidence-based protocol development, enable hospitals to standardize care pathways, and assist payers in evaluating cost-effectiveness of specific treatments and monitoring strategies for reimbursement and coverage policies.
Post-discharge outcomes and prevention research: longitudinal observational studies and interventional trials targeting transition-of-care and secondary prevention in survivors of poisoning, including programs for substance use disorder referral, mental health follow-up, medication safety education, and monitoring for delayed toxic effects. These studies enroll patients discharged after an acute toxic exposure and measure outcomes such as 30- and 90-day readmission, repeat overdose, engagement in outpatient treatment, and long-term functional status. Results are important to providers aiming to reduce recurrent events and to payers interested in downstream cost savings from reduced readmissions and improved outpatient care coordination for this high-risk population.

OpenPayer

Summary & Overview

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

DRG 918 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes